Quick Comparison

CJC-1295 (no DAC)Glutathione
Half-Life0.5 hoursIntracellular: hours (continuously recycled via glutathione reductase) | IV: rapidly distributed to tissues
Typical DosageStandard: 100-300 mcg subcutaneous once to three times daily, typically before bed and/or upon waking. Often combined with Ipamorelin 200-300 mcg in the same injection. Cycled 5 days on, 2 days off, or continuously for 8-12 weeks.IV: 600-2400 mg per session, one to three times weekly. Oral: 500-1000 mg once daily (liposomal forms recommended for better absorption). Intramuscular: 200-600 mg two or three times weekly.
AdministrationSubcutaneous injectionIntravenous, intramuscular, oral (liposomal preferred), or nebulized
Research Papers0 papers33 papers
Categories

Mechanism of Action

CJC-1295 (no DAC)

CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.

When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.

The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.

Glutathione

Glutathione (GSH) is a tripeptide (γ-L-glutamyl-L-cysteinyl-glycine) present in virtually every mammalian cell at concentrations of 1-10 mM, making it the most abundant non-protein thiol and the body's master antioxidant. The cysteine residue provides a reactive sulfhydryl (-SH) group that is the functional center of glutathione's antioxidant activity.

Glutathione's antioxidant mechanism operates through several interconnected pathways. Glutathione peroxidase (GPx) uses GSH as an electron donor to reduce hydrogen peroxide and organic hydroperoxides to water and alcohols, neutralizing these reactive oxygen species before they can damage DNA, proteins, and lipid membranes. In this reaction, two GSH molecules are oxidized to glutathione disulfide (GSSG). Glutathione reductase then regenerates GSH from GSSG using NADPH as the electron donor, maintaining the high GSH/GSSG ratio (typically >100:1) essential for cellular redox homeostasis. Glutathione also directly scavenges hydroxyl radicals, peroxynitrite, and other reactive species, and it regenerates other antioxidants — reducing dehydroascorbate back to vitamin C and restoring oxidized vitamin E.

The detoxification role is equally critical. Phase II conjugation enzymes (glutathione S-transferases, or GSTs) catalyze the attachment of glutathione to electrophilic xenobiotics, drugs, heavy metals, and metabolic byproducts, rendering them water-soluble and targetable for excretion via the kidneys and bile. This is the primary mechanism for detoxifying environmental pollutants, pharmaceutical metabolites, and carcinogenic compounds. For skin brightening, glutathione inhibits melanin synthesis through two mechanisms: it directly inhibits tyrosinase (the rate-limiting enzyme in melanogenesis) and it shifts melanin production from eumelanin (dark brown-black) toward pheomelanin (yellow-red) by conjugating with dopaquinone, redirecting the biosynthetic pathway. This dual mechanism accounts for the skin lightening effect observed with high-dose glutathione supplementation.

Risks & Safety

CJC-1295 (no DAC)

Common

facial flushing, headache, dizziness, injection site irritation.

Serious

overworking the pituitary gland with excessive doses, theoretical risk of promoting existing tumours through elevated growth hormone.

Rare

allergic reactions, fainting.

Glutathione

Common

temporary cramping, flushing, mild nausea during infusion, stomach discomfort with oral forms.

Serious

may interfere with certain chemotherapy drugs; theoretical risk of zinc depletion with long-term high-dose IV use.

Rare

severe allergic reaction from IV administration, Stevens-Johnson syndrome.

Full Profiles